



The New Jersey Department of Health and  
the Centers for Disease Control and Prevention recommend that:

# This patient should be placed on **Contact Precautions** (Note: Nursing homes may implement **Enhanced Barrier Precautions**, if appropriate)

This patient has been identified **OR** awaiting to be ruled out colonization or infection with a novel or targeted multidrug-resistant organism (MDRO). Novel and targeted MDROs may cause long-lasting outbreaks in healthcare facilities and can live in the environment without proper cleaning and disinfection. Implementation of appropriate Transmission-Based Precautions is necessary to prevent outbreaks. **Enhanced Barrier Precautions is not intended for use in acute care or long-term acute care hospitals but is intended for nursing homes** for use as part of a containment strategy for novel and targeted MDROs. **Contact Precautions should be implemented at acute care hospitals; when there is presence of acute diarrhea, draining wounds, secretions or excretions that are unable to be covered or contained, Contact Precautions should be implemented at both acute and long-term care settings.**

## Additional recommendations include:

- This patient should be placed in a **private room**, if available\*
- Healthcare personnel interacting with patients on Contact Precautions, or their environment, are required to wear **gowns and gloves**
- Healthcare personnel interacting with patients on Enhanced Barrier Precautions are required to **wear gowns and gloves** during specific high-contact resident care activities
- Healthcare personnel should conduct diligent **hand hygiene** during and after contact with this patient/environment; Ensure **alcohol-based hand rub** is readily available
- All **cleaning and disinfection** should be performed an product appropriate for the novel or targeted MDRO. For example, units who house an individual colonized or infected with *Candida auris* should utilize a disinfectant with an **Environmental Protection Agency (EPA) registered disinfectant effective against *Candida auris* (List P) or *C. difficile* (List K)**. Environmental cleaning should include:
  - **All equipment** should be cleaned and disinfected after contact with this patient (e.g. stethoscopes, X-ray machines, respiratory therapy equipment)
  - This **patient's room** should be cleaned and disinfected daily and terminally upon discharge
  - **Transport vehicles/equipment** should be terminally cleaned and disinfected after use
- Ensure written and verbal **communication** of isolation status for intra- and inter-facility transfers
- Upon admission, contact the NJ Department of Health Communicable Disease Service at [DOH.CDS.HAIAR.EPI@doh.nj.gov](mailto:DOH.CDS.HAIAR.EPI@doh.nj.gov) to discuss infection prevention and control plan

\*If a patient cannot be placed in a private room, please ensure their roommates are at low risk of developing *Candida* infections. (e.g., are not on antifungal therapies, no indwelling devices, no open wounds)  
This form is to be used with the New Jersey Universal Transfer Form HFEL-7 available at <https://healthapps.state.nj.us/forms/>.

### Resources

- 1) 2019 AR Threats Report | Antibiotic / Antimicrobial Resistance | CDC. <https://www.cdc.gov/drugresistance/biggest-threats.html>
- 2) Containment Strategy Responding to Emerging AR Threats | Healthcare Associated Infections | CDC. <https://www.cdc.gov/hai/containment/index.html>
- 3) PPE in Nursing Homes to Prevent MDROs | HAI | CDC. <https://www.cdc.gov/hai/containment/PPE-Nursing-Homes.html#1>
- 4) Communicable Disease Service | *Candida auris*. <https://nj.gov/health/cd/topics/cauris.shtml>
- 5) Inter-facility IC Transfer Form. <https://www.cdc.gov/hai/pdfs/toolkits/interfacility-IC-Transfer-Form-508.pdf>

Patient Name: \_\_\_\_\_ Completing facility: \_\_\_\_\_

Date completed: \_\_\_\_\_

## Target and Novel Multidrug-resistant Organism Case Transfer Information Sheet

This case status is: (check one)

- Confirmed:** A novel or targeted MDRO was isolated from a body site
- Under investigation\*:** A novel or targeted MDRO is being ruled-out or needs to be ruled out as a result of a known exposure (*NOTE: this is not a confirmed case but should be treated as such until negative results are received*)
- Laboratory results are pending
- Colonization testing is needed

If patient is confirmed to have a novel or targeted MDRO, check one:

- Infection:** Identification during clinical testing
- Infection has been treated and in remission
- Treatment is ongoing
- Colonization:** Identification during surveillance testing

If patient is confirmed to have a novel or target MDRO with a diagnosed organism, check the implicating organism:

- Acinetobacter spp.*       *Candida auris*       *Enterobacter spp.*
- Enterococcus spp.*       *Escherichia coli*       *Klebsiella pneumoniae*
- Pseudomonas aeruginosa*       Other: \_\_\_\_\_

If patient is confirmed to have a novel or target MDRO with an identified carbapenemase gene, check the specific gene:

- IMP       KPC       NDM       VIM       OXA-23       OXA-24/40
- OXA-48       OXA-58       Other: \_\_\_\_\_

The organism was isolated from the patient's: (check all that apply)

- Skin       Blood       Urine       Respiratory Tract       Wound
- Stool       Other: \_\_\_\_\_

The Isolation/Transmission-Based Precaution status at time of discharge:

- Contact       Droplet       Airborne       Enhanced Barrier

Additional notes: \_\_\_\_\_

\* Please contact NJDOH CDS at [DOH.CDS.HAIAR.EPI@doh.nj.gov](mailto:DOH.CDS.HAIAR.EPI@doh.nj.gov) if laboratory testing is needed, or if pending laboratory results are not received within 10 days of transfer.